Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.

Abstract:

:The measurement of plasma clozapine concentrations is useful in assessing compliance, optimizing therapy, and minimizing toxicity. We measured plasma clozapine and norclozapine (N-desmethylclozapine) concentrations in samples from 3782 patients (2648 male, 1127 female). No clozapine was detected in 291 samples (227 patients, median prescribed dose 300 mg/d). In 4963 (50.2 %) samples (2222 patients); plasma clozapine concentration ranged from 10 to 350 ng/mL.Step-wise backward multiple regression analysis (37 % of the total samples) of log10 plasma clozapine concentration against log10 clozapine dose (mg/d), age (year), sex (male = 0, female = 1), cigarette smoking habit (nonsmokers = 0; smokers = 1), body weight (kg), and plasma clozapine/norclozapine ratio (clozapine metabolic ratio, MR) showed that these covariates explained 48% of the observed variation in plasma clozapine concentration (C = ng/mL x 10-3) (P < 0.001) according to the following equation: log 10 (C) = 0.811 log 10 (dose) + 0.332 (MR) + 69.42 X 10 (-3) (sex) + 2.263 x 10 (-3) (age) + 1.976 x 10(-3) (weight) - 0.171 (smoking habit) - 3.180. This model and its associated confidence intervals were used to develop nomograms of plasma clozapine concentration versus dose for male and female smokers and nonsmokers. Predicted plasma clozapine changes by +48% in nonsmokers, +17% in females, +/-8 % for every 0.1 change in MR (reference 1.32), +/-4% for every 5 years (reference 40 years), and +/-5 % for every 10 kg body weight (reference 80 kg). The nomograms can be used (i) to individualize dosage to achieve a given target plasma clozapine concentration, and (ii) for quantitative evaluation of adherence by estimating the likelihood of an observed concentration being achieved by a given dosage regimen. The model has been validated against published data.

journal_name

J Clin Psychopharmacol

authors

Rostami-Hodjegan A,Amin AM,Spencer EP,Lennard MS,Tucker GT,Flanagan RJ

doi

10.1097/01.jcp.0000106221.36344.4d

subject

Has Abstract

pub_date

2004-02-01 00:00:00

pages

70-8

issue

1

eissn

0271-0749

issn

1533-712X

journal_volume

24

pub_type

杂志文章
  • Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal.

    abstract::The aim of this article was to analyze systematically literature information published in English (between 1966 and January 2011) on the efficacy of antidepressants in pediatric obsessive-compulsive disorder. Data were identified through different databases by using variously combined patterns of search terms. Searche...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0b013e31822bb1ff

    authors: Gentile S

    更新日期:2011-10-01 00:00:00

  • Neurocognitive Recovery After Hospital-Treated Deliberate Self-Poisoning With Central Nervous System Depressant Drugs: A Longitudinal Cohort Study.

    abstract::Hospital-treated deliberate self-poisoning (DSP) by central nervous system depressant drugs (CNS-D) has been associated with impairments in cognitive and psychomotor functions at the time of discharge. We aimed to replicate this finding and to compare recovery in the first month after discharge for CNS-D and CNS nonde...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000417

    authors: Oxley SO,Dassanayake TL,Carter GL,Whyte I,Jones AL,Cooper G,Michie PT

    更新日期:2015-12-01 00:00:00

  • Prior Antidepressant Treatment Trials May Predict a Greater Risk of Depressive Relapse During Antidepressant Maintenance Therapy.

    abstract:BACKGROUND:We examined the influence of prior antidepressant treatment trials on the likelihood of depressive relapse, and time to depressive relapse, during maintenance therapy of bipolar II disorder in treatment-responsive subjects who had recovered from a major depressive episode. METHODS:Data were derived from a p...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0000000000001049

    authors: Amsterdam JD,Kim TT

    更新日期:2019-07-01 00:00:00

  • Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.

    abstract::As many as 45% of patients with major depression also meet diagnostic criteria for bipolar (BP) II disorder. Although the use of a concurrent mood-stabilizing drug has been suggested in treating BP II depression, antidepressant monotherapy has received less attention. The efficacy and safety of venlafaxine were examin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199810000-00010

    authors: Amsterdam J

    更新日期:1998-10-01 00:00:00

  • A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.

    abstract::Patients with obsessive-compulsive disorder (OCD) have been shown to be preferentially responsive to serotonin (5-HT) uptake-inhibiting antidepressants including clomipramine, fluoxetine, fluvoxamine, and sertraline. The nontricyclic antidepressant, trazodone, also possesses serotonin reuptake inhibiting properties an...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Pigott TA,L'Heureux F,Rubenstein CS,Bernstein SE,Hill JL,Murphy DL

    更新日期:1992-06-01 00:00:00

  • Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.

    abstract::The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment. A total of 131 inpatients with acutely ill MDD were enrolled to receive 20 mg of fluoxetine daily...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000410

    authors: Lin HS,Wang FC,Lin CH

    更新日期:2015-12-01 00:00:00

  • Interrater reliability of the modified Monitoring of Side Effects Scale for assessment of adverse effects of psychiatric medication in clinical and research settings.

    abstract::The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000311

    authors: Nugent KL,Spahr E,Toroney J,Mojtabai R,Nettles C,Turner LW,Fenton A,Spivak A,Cullen BA,Everett A,Eaton WW

    更新日期:2015-06-01 00:00:00

  • Fluoxetine and Risk of Bleeding in Patients Aged 60 Years and Older Using the Korea Adverse Event Reporting System Database: A Case/Noncase Study.

    abstract:BACKGROUND:Depression, the leading cause of nonfatal disease burden, has a strong correlation with suicide and affects approximately 7% of the general elderly population. Adverse drug reactions in older patients are particularly important because of reduced drug metabolism, polypharmacy, drug-drug interactions, and dru...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001059

    authors: Kim S,Ko YJ,Park K,Yang BR,Kim MS,Park BJ

    更新日期:2019-07-01 00:00:00

  • Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.

    abstract::The pharmacokinetics of drugs with specific binding sites in the brain needs to be evaluated at these sites. In this study, we measured the time course of the selective serotonin reuptake inhibitor fluvoxamine in the human brain based on serotonin transporter (5-HTT) occupancy by positron emission tomography. Consecut...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000203201.34323.d3

    authors: Takano A,Suhara T,Ichimiya T,Yasuno F,Suzuki K

    更新日期:2006-04-01 00:00:00

  • Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

    abstract::This research compared the long-term efficacy and safety of iloperidone with those of haloperidol in individuals with schizophrenia. Data were pooled from 3 prospective multicenter studies, each with 6-week stabilization followed by 46-week double-blind maintenance phases. Patients were randomized to iloperidone 4 to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0b013e318169cca7

    authors: Kane JM,Lauriello J,Laska E,Di Marino M,Wolfgang CD

    更新日期:2008-04-01 00:00:00

  • Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.

    abstract::Fifty-five patients completed a 5-week double-blind study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. There was no concomitant behavioral treatment. Patient and therapist rating scales included Sheehan's Panic and Anxiety Attack Scales, the Mark...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Munjack DJ,Crocker B,Cabe D,Brown R,Usigli R,Zulueta A,McManus M,McDowell D,Palmer R,Leonard M

    更新日期:1989-02-01 00:00:00

  • α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.

    abstract:PURPOSE:The aim of this article is to review the recent trials of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists and positive allosteric modulators (PAMs) on the treatment of cognitive decline in schizophrenia. α7 Nicotinic acetylcholine receptor abnormalities in schizophrenia and clinical implications of α7 n...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0000000000000859

    authors: Jones C

    更新日期:2018-06-01 00:00:00

  • Risperidone for the treatment of stuttering.

    abstract::A randomized, double-blind, placebo-controlled study was conducted to assess the efficacy of risperidone in the treatment of developmental stuttering in 16 adults. Eight subjects received placebo and eight received risperidone at 0.5 mg once daily at night, increased to a maximum of 2 mg/day. After 6 weeks of treatmen...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200008000-00013

    authors: Maguire GA,Riley GD,Franklin DL,Gottschalk LA

    更新日期:2000-08-01 00:00:00

  • Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine.

    abstract::There have been many attempts to find predictors of the therapeutic response to the clomipramine treatment of obsessive-compulsive disorder. The majority of studies have failed to identify such predictors. Possible reasons for this failure include the small sample size of most studies, samples homogeneous with respect...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Ackerman DL,Greenland S,Bystritsky A,Morgenstern H,Katz RJ

    更新日期:1994-08-01 00:00:00

  • Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.

    abstract:BACKGROUND:Sexual dysfunction (SD) is an important underestimated adverse effect of antidepressant drugs. Patients, in fact, if not directly questioned, tend to scarcely report them. The aim of the present meta-analysis was to quantify SD caused by antidepressants on the basis of studies where sexual functioning was pu...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/JCP.0b013e3181a5233f

    authors: Serretti A,Chiesa A

    更新日期:2009-06-01 00:00:00

  • A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis.

    abstract::This study evaluates how much agreement there is between subjective reports of adherence to antipsychotic medication and objective or derived measures of adherence in first-episode psychosis (FEP) and asks if any adherence measure could approximate a gold standard based on correlation to symptom improvement in the ear...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181ca03df

    authors: Cassidy CM,Rabinovitch M,Schmitz N,Joober R,Malla A

    更新日期:2010-02-01 00:00:00

  • Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.

    abstract::The aim of this study was to estimate the long-term effectiveness of olanzapine as adjunctive therapy in patients with bipolar disorder who exhibited an inadequate response to mood stabilizers. Twenty-three Research Diagnostic Criteria (RDC) patients with bipolar I and II were assessed by means of the Schedule for Aff...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200110000-00002

    authors: Vieta E,Reinares M,Corbella B,Benabarre A,Gilaberte I,Colom F,Martínez-Arán A,Gastó C,Tohen M

    更新日期:2001-10-01 00:00:00

  • Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts.

    abstract::Nitrous oxide (laughing gas) has shown early promise as a rapidly acting antidepressant in patients with treatment-resistant major depression and is currently investigated in several clinical trials. Because nitrous oxide is rarely administered outside operating rooms or dental practices, most psychiatrists are not fa...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0000000000000837

    authors: Nagele P,Zorumski CF,Conway C

    更新日期:2018-04-01 00:00:00

  • Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program.

    abstract:PURPOSE/BACKGROUND:The Phase 3 program for RBP-7000, a once-monthly subcutaneous (SC) extended-release risperidone formulation approved for treatment of schizophrenia, consisted of a double-blind placebo-controlled trial (previously reported) and a 52-week open-label study of monthly RBP-7000 120 mg. The primary object...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/JCP.0000000000001076

    authors: Andorn A,Graham J,Csernansky J,Newcomer JW,Shinde S,Muma G,Heidbreder C,Fava M

    更新日期:2019-09-01 00:00:00

  • Effect of erythromycin on tricyclic antidepressant metabolism.

    abstract::Macrolide antibiotics such as erythromycin have been found to impair the hepatic metabolism of carbamazepine. In addition, recent studies have shown that intestinal flora can N-demethylate tricyclic antidepressants, suggesting that the human gut may be a possible site of extrahepatic drug metabolism. Therefore, we con...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Amsterdam JD,Maislin G

    更新日期:1991-06-01 00:00:00

  • Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?

    abstract::Seventeen hospitalized psychotic patients were treated with a fixed oral dose of haloperidol, 5 mg twice daily for 28 days. Most were chronic schizophrenics with an acute exacerbation of their illness. All patients also received benztropine 3 mg twice daily during the last 11 days of the study, regardless of the prese...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Shostak M,Perel JM,Stiller RL,Wyman W,Curran S

    更新日期:1987-12-01 00:00:00

  • Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.

    abstract::Weight gain is a problem commonly encountered with antipsychotic treatment and has become more apparent with increasing use of the newer atypical antipsychotics. The adipocyte-derived hormone, leptin, has been associated with body weight and energy homeostasis, and abnormal regulation of leptin could play a role in we...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/jcp.0b013e3180582412

    authors: Zhang XY,Tan YL,Zhou DF,Haile CN,Cao LY,Xu Q,Shen Y,Kosten TA,Kosten TR

    更新日期:2007-06-01 00:00:00

  • The effect of chronic alprazolam on sleep and bioamine metabolites in depression.

    abstract::Alprazolam administered for 43 days in doses of 6 to 10 mg/day had an antidepressant effect in four of nine depressed patients. Decreases in slow wave sleep, increases in rapid eye movement (REM) latency, and decreases in REM minutes and percent and REM sleep eye movements were found in the group as a whole. The drug ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Zarcone VP Jr,Benson KL,Greene KA,Csernansky JG,Faull KF

    更新日期:1994-02-01 00:00:00

  • Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder.

    abstract::Twenty-one women with generalized anxiety disorder (GAD) participated in a 6-week, double-blind, placebo-controlled trial to assess the treatment and abrupt withdrawal effects of diazepam on psychic and somatic symptoms of anxiety. The results confirmed those of previous studies reporting that (1) clinical doses of di...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199606000-00002

    authors: Pourmotabbed T,Mcleod DR,Hoehn-Saric R,Hipsley P,Greenblatt DJ

    更新日期:1996-06-01 00:00:00

  • Improving treatment of depression in the elderly: two innovations in statistical design of clinical trials.

    abstract::Depression in the elderly patient may present special challenges for the design of clinical treatment trials due to a complex antidepressant treatment history, individual contraindications to certain medications, medical comorbidity, as well as concurrent medications for other medical conditions. The chronic, relapsin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.jcp.0000168502.16361.ad

    authors: Lavori PW

    更新日期:2005-08-01 00:00:00

  • Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid.

    abstract::In an open prospective clinical study, 14 female outpatients with anorexia nervosa or bulimia completed a 6-week trial of isocarboxazid, with a mean dose of 34 mg. The eight bulimic and six restrictive anorexic subjects did not show any significant differences in medication response. Ratings of depression and anxiety ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-198510000-00005

    authors: Kennedy SH,Piran N,Garfinkel PE

    更新日期:1985-10-01 00:00:00

  • Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial.

    abstract:OBJECTIVE:Craving, an urge or increased desire to take a drug, is part of a cluster of behavioral, cognitive, and physiological phenomena that can develop after substance use. Self-reported cravings for heroin and cocaine are compared in opioid dependent patients while receiving maintenance treatment with slow-release ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000288

    authors: Falcato L,Beck T,Reimer J,Verthein U

    更新日期:2015-04-01 00:00:00

  • Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

    abstract::The optimal treatment for schizoaffective disorder (SCA) is not well established. In this initial 6-month open-label treatment period of a large, multiphase, relapse-prevention study, the efficacy and safety of paliperidone palmitate once-monthly (PP1M) injectable were evaluated in subjects with symptomatic SCA. Subje...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000535

    authors: Fu DJ,Turkoz I,Simonson RB,Walling D,Schooler N,Lindenmayer JP,Canuso C,Alphs L

    更新日期:2016-08-01 00:00:00

  • 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.

    abstract:BACKGROUND:Pathological gambling (PG) is a relatively common and highly disabling impulse control disorder. A range of psychotherapeutic agents including selective serotonin reuptake inhibitors, antiepileptic drugs, and opioid antagonists are shown to be effective in the short-term treatment of PG. The use of a wide ra...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/jcp.0b013e31815a4400

    authors: Dannon PN,Lowengrub K,Musin E,Gonopolsky Y,Kotler M

    更新日期:2007-12-01 00:00:00

  • Comparative abuse liability of intravenously administered remifentanil and fentanyl.

    abstract::Remifentanil is a short-acting, esterase-metabolized opioid analgesic. This study compared the abuse liability of remifentanil with that of fentanyl and placebo in a randomized, double-blind, crossover study. Twelve recreational users of opioids received increasing doses of remifentanil (0.6, 1.2, 1.8, 2.4, and 3.0 mi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200012000-00002

    authors: Baylon GJ,Kaplan HL,Somer G,Busto UE,Sellers EM

    更新日期:2000-12-01 00:00:00